AstraZeneca says that its experimental gout drug lesinurad failed to hit the primary biomarker target for the dose that it's now seeking regulatory approval for in the U.S. and Europe. And this latest Phase III--the last of a trio--continues to demonstrate that the pharma giant can't land evidence that the drug provides a clear benefit to patients in the time allotted for the study.
Last week, Briggs Morrison was the head of late-stage development and chief medical officer at AstraZeneca with responsibility for leading the turnaround at one of the world's biggest pharma pipelines with thousands of staffers, dozens of clinical-stage programs and a budget that's in the billions. This week, he's moving to a new job as CEO of Syndax Pharmaceuticals.
An electronic health record-enabled data dive has turned up links between proton pump inhibitors and a 16% to 20% increase in the risk of heart attack.
Briggs Morrison, the executive vice president for R&D at AstraZeneca and a major player in the pharma company's turnaround attempt over the past three years, is leaving the pharma giant, FierceBiotech has learned.
A trio of insider traders banked about $530,000 on tips from within Ardea Biosciences, according to the SEC, buying shares ahead of major news right up until AstraZeneca bought the company for $1.3 billion.
Just weeks after AstraZeneca said it would build a new facility in Sweden where it intends to fill and package biologics, the U.K. drugmaker said it was doing something more traditional in Algeria. Through a joint venture there, it will build a $125 million small-molecule plant.
The data pump is going full tilt at the American Diabetes Association meeting, with top drugmakers rolling out studies on their top drugs, new and old. From new safety analyses to head-to-head match-ups, here's a roundup of the need-to-know.
AstraZeneca CEO Pascal Soriot has made emerging markets part of his 5-point campaign to rebuild the drugmaker's financial health. And now he is taking that piece of his campaign to North Africa, where AstraZeneca is part of a joint venture to build a $125 million plant.
Anyone looking for an example of just how easy it is to start a biotech buyout rumor these days need look no further than Bloomberg 's report on AstraZeneca's Pascal Soriot earlier in the week.
AstraZeneca CEO Pascal Soriot, under pressure to boost the U.K. company's financials after thumbing its nose at a $100+ billion takeover by Pfizer, is sniping at U.K. regulators for refusing to pay for a new ovarian cancer treatment that the U.S. and Europe have approved.